Controversies of hepatectomy and adjuvant therapy for hepatocellular carcinoma: moving forward

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Zhong JH,You XM,Xiang X.Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study..Oncotarget2017;8:18296-302 PMCID:PMC5392328

[3] Zhong JH,Gong WF,Ma L.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma..Ann Surg2014;260:329-40

[4] A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators..Hepatology1998;28:751-5

[5] Chevret S,Mathieu D,Beaugrand M.A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire..J Hepatol1999;31:133-41

[6] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification..Semin Liver Dis1999;19:329-38

[7] Sang W,Chan AW.Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients..Eur J Cancer2016;63:203-5

[8] Zhou J,Wang Z,Wang JH.Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition)..Liver Cancer2018;7:235-60 PMCID:PMC6167671

[9] Leung TW,Zee B,Lai PB.Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients..Cancer2002;94:1760-9

[10] Yau T,Yao TJ,Lo CM.Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma..Gastroenterology2014;146:1691-700

[11] Kudo M,Osaki Y.Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging score (JIS score)..J Gastroenterol2003;38:207-15

[12] Farinati F,Spolverato G,Huo TL.Development and validation of a new prognostic system for patients with hepatocellular carcinoma..PLoS Med2016;13:e1002006 PMCID:PMC4846017

[13] European Association for the Study of the LiverEASL clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[14] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[15] Kolly P,Sangro B,Candinas D.Assessment of the Hong Kong Liver Cancer Staging System in Europe..Liver Int2016;36:911-7

[16] Kim KM,Jung SH,Paik YH.The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?.Liver Int2016;36:1490-7

[17] Bolondi L,Dufour JF,Mazzaferro V.Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions..Semin Liver Dis2012;32:348-59

[18] Mo DC,Zhong JH.Hepatic resection compared to chemoembolization in intermediate to advanced-stage HCC: a comment for moving forward..Hepatology2018;Epub ahead of print, DOI: 10.1002/hep.30409

[19] Wang YY,Xu HF,Wang LJ.A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria..Aliment Pharmacol Ther2019;49:202-10

[20] Zhong JH,Ke Y,Wang L.Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion..Medicine (Baltimore)2015;94:e396 PMCID:PMC4602643

[21] Zhong JH,Li H.Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma..Tumour Biol2014;35:8355-8

[22] Hyun MH,Kim JH,Jung YK.Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies..Hepatology2018;68:977-93

[23] Yuan BH,Li RH,Gong WF.Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma..Tumour Biol2016;37:2435-41

[24] Peng ZW,Zhang YJ,Chen MS.Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus..Cancer2012;118:4725-36

[25] Kokudo T,Matsuyama Y,Izumi N.Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion..J Hepatol2016;65:938-43

[26] Kokudo T,Matsuyama Y,Izumi N.Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey..Hepatology2017;66:510-7

[27] de la Torre MA,de la Rosa PA,Bustamante FJ.A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib..Liver Int2016;36:1206-12

[28] Xiang X, Lau WY, Wu ZY, Zhao C, Ma YL, et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. EJSO 2019. Available from: https://www.ejso.com/article/S0748-7983(19)30387-7/abstract. [Last accessed on 23 Apr 2019]

[29] Zhong JH,Xing H,Han J.Controversies and evidence of hepatic resection for hepatocellular carcinoma..BBA Clin2016;6:125-30 PMCID:PMC5067978

[30] Zhong JH,Xiang BD,Yang T.We’re still in an update process of the BCLC system..Ann Surg2018;267:e23-e4

[31] Zhong JH.Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis..Hepatol Res2010;40:943-53

[32] Huang G,Wang ZG,Yuan SX.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial..Ann Surg2015;261:56-66

[33] Huang G,Lau WY,Zhao LH.Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial..Ann Surg2018;268:943-54

[34] Shen YC,Chen LT,Hu FC.Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach..J Hepatol2010;52:889-94

[35] Mo HY,You XM,Yuan BH.Timely meta-analysis on the efficacy of adoptive immunotherapy for hepatocellular carcinoma patients after curative therapy..PLoS One2017;12:e0174222 PMCID:PMC5365130

[36] Zhong JH,Xiang BD,Jiang JF.Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma..PLoS One2013;8:e58082 PMCID:PMC3591458

[37] Zhong JH,Li LQ.Postoperative therapy options for hepatocellular carcinoma..Scand J Gastroenterol2014;49:649-61

[38] Zhong JH,Li LQ.Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review..Tumour Biol2014;35:9459-68

[39] Bruix J,Mazzaferro V,Yang J.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial..Lancet Oncol2015;16:1344-54